Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Or call (215) 966-6061
Questions? Call: 215-966-6061
Virology reagents for neutralization assays: ideal for therapeutic antibody and vaccine development
Home » Vaccine Development
“SARS-CoV-2 RVPs really helped us a lot since we did not have much previous expertise in SARS. The user meetings were especially helpful.”
-YUFEI XIANG, UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Learn more about our most popular products:
> SARS-CoV-2 variant Reporter Virus Particles
> Influenza Reporter Virus Particles
> Filovirus Reporter Virus Particles
> Dengue and Zika RVP case study
Deep expertise in virology is at the core of Integral Molecular’s 20-year history, and we have co-authored over 70 peer-reviewed virology publications in journals including Cell, Science and Nature. With the support of NIAID, scientists at Integral Molecular have been on the forefront of combatting viral epidemics including COVID-19, Zika, Ebola, and Chikungunya. Meet our team.
Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery, and antibody discovery against viral targets.
Yes. We can produce large lots of RVPs to accommodate screening 100s or 1000s of samples in sera neutralization assays without bridging studies.
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Join Our Mailing List